AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30604091 — intervention group
Group type: EXPERIMENTAL
Intervention: LY IGlar
Number of subjects: 493
Study 28556598 — intervention group
Group type: EXPERIMENTAL
Intervention: Epelsiban 300 mg twice daily for 1 day
Number of subjects: 43
Study 28556598 — intervention group
Group type: COMPARATOR
Intervention: Epelsiban 200 mg 3 times daily for 14 days
Number of subjects: 43
Study 28556598 — intervention group
Group type: COMPARATOR
Intervention: Epelsiban 300 mg 3 times daily for 14 days
Number of subjects: 43
Study 28556598 — intervention group
Group type: COMPARATOR
Intervention: Epelsiban 450 mg twice daily for 14 days
Number of subjects: 43
Study 28556598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 28556598 — intervention group
Group type: EXPERIMENTAL
Intervention: Epelsiban 600 mg and 900 mg total daily doses
Number of subjects: 43
Study 26505571 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncompressible warming mattress (Baby/Kleinkinddecke of MoeckWarmingSystems, Moeck und Moeck GmbH; group MM) at 40°C
Number of subjects: 80
Study 26505571 — intervention group
Group type: COMPARATOR
Intervention: Compressible warming mattress system (Pediatric Underbody, Bair Hugger, 3M; group BH) at 43°C
Number of subjects: 80
Study 26505571 — intervention group
Group type: COMPARATOR
Intervention: Compressible warming mattress system (group BH)
Number of subjects: 80
Study 26505571 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncompressible warming mattress (group MM)
Number of subjects: 80
Study 26505571 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 80
Study 23768191 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 1034
Study 23768191 — intervention group
Group type: COMPARATOR
Intervention: Sham electro-acupuncture
Number of subjects: 1034
Study 21490024 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxycodone (OOXY)
Number of subjects: 110
Study 19763803 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine
Number of subjects: 0
Study 19763803 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study 19763803 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16766975 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (VAC) for hematomas
Number of subjects: 88
Study 16766975 — intervention group
Group type: COMPARATOR
Intervention: Pressure dressing for hematomas (group A)
Number of subjects: 88
Study 16766975 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (VAC) for fractures
Number of subjects: 88
Study 16766975 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative dressing for fractures (group A)
Number of subjects: 88
Study 15636140 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloferon
Number of subjects: 16000
Study 15636140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16000
Study 11134474 — intervention group
Group type: EXPERIMENTAL
Intervention: Adderall (0.15 mg/kg/dose and 0.3 mg/kg/dose)
Number of subjects: 154
Study 11134474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 9211209 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention community worksites with no smoke-free policy at baseline
Number of subjects: 0
Study 9211209 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention community worksites with no cessation assistance at baseline
Number of subjects: 0
Study 9211209 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksites employing 100 to 249 workers
Number of subjects: 0
Study 9211209 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksites predominantly employing men
Number of subjects: 0
Study 9211209 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksites offering other types of health-promotion activities
Number of subjects: 0
Study 9211209 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksites with a higher rate of turnover
Number of subjects: 0
Study 9211209 — intervention group
Group type: COMPARATOR
Intervention: Manufacturing businesses
Number of subjects: 0
Study 8394815 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin (400 mg once daily)
Number of subjects: 70
Study 8394815 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin (400 mg twice daily)
Number of subjects: 70
Study 8394815 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin
Number of subjects: 70
Study 8394815 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin
Number of subjects: 70
Study 3333985 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative functional treatment
Number of subjects: 80
Study 3333985 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 80
Study 29989055 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle assisted pushing (GAP)
Number of subjects: 1158
Study 29989055 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright position
Number of subjects: 1158
Study 29989055 — intervention group
Group type: COMPARATOR
Intervention: Routine practice (recumbent posture)
Number of subjects: 1158
Study 29989055 — intervention group
Group type: EXPERIMENTAL
Intervention: GAP and Upright position
Number of subjects: 1158
Study 29989055 — intervention group
Group type: COMPARATOR
Intervention: Routine practice
Number of subjects: 1158
Study 26602318 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberry treatment (300g of blueberries) + smoking (one cigarette)
Number of subjects: 14
Study 26602318 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (300ml of water with sugar) + smoking (one cigarette)
Number of subjects: 14
Study 26602318 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking treatment (one cigarette)
Number of subjects: 14
Study 24517142 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin-54 (0.01, 0.03, 0.10, 0.30, or 1.00 nmol/kg/h)
Number of subjects: 5
Study 24517142 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 5
Study 23766644 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily health status measurements during outpatient treatment or admission to hospital.
Number of subjects: 255
Study 23766644 — intervention group
Group type: EXPERIMENTAL
Intervention: CCQ symptom score (Clinical COPD Questionnaire).
Number of subjects: 255
Study 23766644 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status and gender.
Number of subjects: 255
Study 23766644 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, forced expiratory flow in one second % predicted, smoking status, and CCQ score.
Number of subjects: 255
Study 23766644 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status measurements in outpatient management.
Number of subjects: 255
Study 20542854 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone administration of outcome measures
Number of subjects: 19
Study 20542854 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face administration of outcome measures
Number of subjects: 19
Study 18447217 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Hegu (LI 4) and Taichong (LR 3) with Qinglong Baiwei method
Number of subjects: 180
Study 18447217 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine acupuncture with Sanyinjiao (SP 6) and Ciliao (BL 32)
Number of subjects: 180
Study 18447217 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Yueyueshu Decoction
Number of subjects: 180
Study 19436938 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenic Obese (SO)
Number of subjects: 183
Study 19436938 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenic (SS)
Number of subjects: 183
Study 19436938 — intervention group
Group type: COMPARATOR
Intervention: Normal Lean (NL)
Number of subjects: 183
Study 19436938 — intervention group
Group type: COMPARATOR
Intervention: Obese (OO)
Number of subjects: 183
Study 19436938 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Appendicular Skeletal Muscle Mass (ASM)
Number of subjects: 183
Study 19436938 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ASM
Number of subjects: 183
Study 15805349 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy at 67 microg/kg per day
Number of subjects: 28
Study 15805349 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy at 33 microg/kg per day
Number of subjects: 28
Study 15805349 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose regimen (> or =50 microg/kg per day) followed by tapering to approximately 33 microg/kg per day
Number of subjects: 28
Study 15805349 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 28
Study 12412977 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP-HFA (beclomethasone dipropionate aerosol spray 500 microg b.i.d. via Jet spacer)
Number of subjects: 154
Study 12412977 — intervention group
Group type: COMPARATOR
Intervention: CFC (beclomethasone dipropionate aerosol spray 500 microg b.i.d. via Jet spacer)
Number of subjects: 154
Study 12412977 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP-HFA
Number of subjects: 154
Study 12412977 — intervention group
Group type: COMPARATOR
Intervention: CFC
Number of subjects: 154
Study 9494308 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative anxiety measured by State Anxiety Inventory Scale on postoperative day 2 and day 3.
Number of subjects: 0
Study 9494308 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective pain measured by McGill Pain Questionnaire Subscales on postoperative day 2.
Number of subjects: 0
Study 9494308 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity and sensory pain measured by McGill Pain Questionnaire Subscales on postoperative day 2 and day 3.
Number of subjects: 0
Study 8049037 — intervention group
Group type: EXPERIMENTAL
Intervention: Romberg standing test
Number of subjects: 20
Study 8049037 — intervention group
Group type: EXPERIMENTAL
Intervention: Unterberger treading test
Number of subjects: 20
Study 3378514 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50mg twice daily with sustained release nifedipine 20mg twice daily
Number of subjects: 25
Study 3378514 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50mg twice daily with sustained release nifedipine 40mg twice daily
Number of subjects: 25
Study 3378514 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50mg twice daily
Number of subjects: 25
Study 3378514 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 25
Study 12802138 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamotion video intervention
Number of subjects: 208
Study 30157365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ningmitai Capsules (NMT)
Number of subjects: 40
Study 30157365 — intervention group
Group type: COMPARATOR
Intervention: Terazosin hydrochloride tablets
Number of subjects: 40
Study 26501499 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment (N = 33)
Number of subjects: 67
Study 26501499 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (waitlist-control, N = 34)
Number of subjects: 67
Study 25099298 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Job Interview Training (VR‐JIT)
Number of subjects: 37
Study 25099298 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 37
Study 22147900 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial PCI
Number of subjects: 2977
Study 22147900 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral PCI
Number of subjects: 2977
Study 19716278 — intervention group
Group type: EXPERIMENTAL
Intervention: LABA treatment
Number of subjects: 20
Study 19716278 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 20
Study 18549841 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang (XZK)
Number of subjects: 5000
Study 18549841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5000
Study 16028789 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aid use
Number of subjects: 102
Study 16028789 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hearing aid)
Number of subjects: 102
Study 12075846 — intervention group
Group type: EXPERIMENTAL
Intervention: Reports of controlled trials identified from AMI
Number of subjects: 512
Study 12075846 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of indexing of trials in AMI
Number of subjects: 512
Study 10619101 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificially loaded healthy subjects carrying load in the hand
Number of subjects: 0
Study 10619101 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal subjects carrying load on the ankles
Number of subjects: 0
Study 7669477 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine 3.5 ml
Number of subjects: 30
Study 7669477 — intervention group
Group type: COMPARATOR
Intervention: 0.5% hyperbaric bupivacaine 3 ml
Number of subjects: 30
Study 2257867 — intervention group
Group type: EXPERIMENTAL
Intervention: SCR 4 mg
Number of subjects: 15
Study 2257867 — intervention group
Group type: EXPERIMENTAL
Intervention: SCR 8 mg
Number of subjects: 15
Study 2257867 — intervention group
Group type: COMPARATOR
Intervention: SCR 4 mg and SCR 8 mg
Number of subjects: 15
Study 36117 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 0
Study 36117 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2-2.5 mg
Number of subjects: 0
Study 36117 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam i.v.
Number of subjects: 0
Study 36117 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study 31092044 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth mindfulness intervention for 8 weeks
Number of subjects: 128
Study 31092044 — intervention group
Group type: COMPARATOR
Intervention: Usual care (wait-list control group)
Number of subjects: 128
Study 29443538 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic hip surgery
Number of subjects: 80
Study 29443538 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (12-session supervised clinic program)
Number of subjects: 80
Study 26920590 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES) - sirolimus-eluting stents (SES) and everolimus-eluting stents (EES)
Number of subjects: 2314
Study 26920590 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 2314
Study 26920590 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 2314
Study 25066876 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day mifepristone-misoprostol interval
Number of subjects: 217
Study 25066876 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day mifepristone-misoprostol interval
Number of subjects: 217
Study 25066876 — intervention group
Group type: COMPARATOR
Intervention: Control group (same-day reports)
Number of subjects: 217
Study 22913680 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (banding 19%, vertical banded gastroplasty 69%, gastric bypass 12%)
Number of subjects: 1658
Study 22913680 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1658
Study 20477774 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy drinking
Number of subjects: 0
Study 20477774 — intervention group
Group type: EXPERIMENTAL
Intervention: Average drinks per drinking day
Number of subjects: 0
Study 20477774 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of drinking
Number of subjects: 0
Study 20477774 — intervention group
Group type: EXPERIMENTAL
Intervention: Total drinks per month
Number of subjects: 0
Study 20477774 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of drinking changes
Number of subjects: 0
Study 20477774 — intervention group
Group type: EXPERIMENTAL
Intervention: Other factors predicting drinking change
Number of subjects: 0
Study 17716499 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital heart disease (35%)
Number of subjects: 58
Study 17716499 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal hypertensive disease (26%)
Number of subjects: 58
Study 17716499 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatic heart disease (17%)
Number of subjects: 58
Study 17716499 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiomyopathies (12%)
Number of subjects: 58
Study 17716499 — intervention group
Group type: EXPERIMENTAL
Intervention: Endomyocardial fibrosis (7%)
Number of subjects: 58
Study 17716499 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamponade (3%)
Number of subjects: 58
Study 16376250 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial cement used in total knee arthroplasty (30 knees)
Number of subjects: 57
Study 16376250 — intervention group
Group type: COMPARATOR
Intervention: No tibial cement used in total knee arthroplasty (30 knees)
Number of subjects: 57
Study 12075703 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy to the chest after resection for Stage II and IIIA NSCLC
Number of subjects: 0
Study 12075703 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy for Stage IIIA NSCLC
Number of subjects: 0
Study 12075703 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Number of subjects: 0
Study 12075703 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation
Number of subjects: 0
Study 12075703 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapies
Number of subjects: 0
Study 11390029 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcarnosine, 1% sol (NAC)
Number of subjects: 49
Study 11390029 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo and untreated)
Number of subjects: 49
Study 9581951 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse polarity (RV apex = anode)
Number of subjects: 60
Study 9581951 — intervention group
Group type: COMPARATOR
Intervention: Normal polarity (RV apex = cathode)
Number of subjects: 60
Study 9581951 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse polarity (RV apex = anode) in patients with high DFT (> or = 15 J)
Number of subjects: 60
Study 9581951 — intervention group
Group type: COMPARATOR
Intervention: Normal polarity (RV apex = cathode) in patients with high DFT (> or = 15 J)
Number of subjects: 60
Study 7924900 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-linolenic acid (EPO, Epogam, Searle, U.K.)
Number of subjects: 0
Study 7924900 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-linolenic acid (high dose EPO)
Number of subjects: 0
Study 7924900 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-linolenic acid (EPO)
Number of subjects: 0
Study 3287911 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 40 mg once daily for two days, then 20 mg daily for five days
Number of subjects: 74
Study 3287911 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily for five days
Number of subjects: 74
Study 4616802 — intervention group
Group type: EXPERIMENTAL
Intervention: Duphalac (lactulose preparation)
Number of subjects: 164
Study 4616802 — intervention group
Group type: COMPARATOR
Intervention: Irritant laxatives (containing senna, anthraquinone derivatives, or bisacodyl)
Number of subjects: 164
Study 31565796 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT) 2 days/week at the clinic with adherence support
Number of subjects: 48
Study 31565796 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with two AIT sessions and encouraged to exercise on their own
Number of subjects: 48
Study 28600159 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MedDiet) alone, without weight loss
Number of subjects: 180
Study 28600159 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet lifestyle intervention to promote weight loss and weight loss maintenance
Number of subjects: 180
Study 28600159 — intervention group
Group type: COMPARATOR
Intervention: Typical Diet Control
Number of subjects: 180
Study 28600159 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MedDiet intervention groups
Number of subjects: 180
Study 26153197 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiotic tablet (1 tablet daily for 8 weeks)
Number of subjects: 44
Study 26153197 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet (1 tablet daily for 8 weeks)
Number of subjects: 44
Study 26153197 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiotic tablet
Number of subjects: 44
Study 23332327 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention group (15-month intervention targeting organizational and environmental changes)
Number of subjects: 1257
Study 23332327 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention group
Number of subjects: 1257
Study 23332327 — intervention group
Group type: COMPARATOR
Intervention: Delayed control group (no intervention during the 15-month period)
Number of subjects: 1257
Study 21839689 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 52
Study 21839689 — intervention group
Group type: COMPARATOR
Intervention: Education (EDU)
Number of subjects: 52
Study 19179316 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive 6-month weight-loss program (diet, exercise, behavior modification)
Number of subjects: 338
Study 19179316 — intervention group
Group type: COMPARATOR
Intervention: Structured education program
Number of subjects: 338
Study 17002709 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (200 mcg once daily for 4 weeks)
Number of subjects: 20
Study 17002709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15284344 — intervention group
Group type: EXPERIMENTAL
Intervention: l‐NAME (4 mg kg(‐1) in 50 ml saline)
Number of subjects: 7
Study 15284344 — intervention group
Group type: COMPARATOR
Intervention: Placebo (50 ml saline)
Number of subjects: 7
Study 11712229 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (inspiratory concentration of oxygen raised from 0.4 to 1.0 for 15 minutes)
Number of subjects: 22
Study 11712229 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (control group, FiO2 0.4)
Number of subjects: 22
Study 9113184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 0.625 microgram/kg
Number of subjects: 24
Study 9113184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 1.25 micrograms/kg
Number of subjects: 24